Amoneta Diagnostics at AD/PD™ 2025

APO-Easy® Genotyping kit in the Context of New Therapies' Launch

Amoneta Diagnostics is pleased to announce its’ team’s participation to the AD/PD™ 2025 conference, a major international event that brings together experts in the field

of Alzheimer’s and Parkinson’s disease. This year, the focus will be on APO-Easy®, our CE-IVDR certified genotyping kit that is designed to assess genetic risk for Alzheimer’s disease through the analysis of the APOE gene.

With the launch of groundbreaking new treatments for Alzheimer’s disease, the need for identifying patients who may benefit from such therapies has never been more urgent.

Alzheimer’s disease is a complex, multifactorial condition influenced by both genetic and environmental factors. Among the various genetic markers, the APOE gene

(Apolipoprotein E) is one of the most significant, with three main variants: APOE ε2, APOE ε3, and APOE ε4. The APOE ε4 allele is linked to a higher risk of developing

Alzheimer’s disease, particularly in those who carry one or two copies of this allele.

Leqembi and Kisunla are anti-amyloid treatments that are primarily beneficial for individuals with Alzheimer’s who exhibit amyloid plaques. Their use should be carefully

considered in those with the APOE ε4 allele due to an increased risk of side effects like ARIA (Amyloid-Related Imaging Abnormalities).

In this process, APO-Easy® offers a simple, reliable way to detect the APOE ε4 allele. This non-invasive test not only provides insights into an individual’s genetic

predisposition but also helps determine eligibility for treatments. By identifying individuals at higher risk, the APO-Easy® genotyping kit helps guide treatment decisions and ensures that the right patients receive the right therapies at the right time, advancing precision medicine and improving quality of life for patients.

We are excited to showcase APO-Easy® at AD/PD™ 2025 and explore how this product, in conjunction with emerging therapies like Leqembi and Kisunla, is shaping the

future of Alzheimer's care. We invite you to visit our booth #27 to learn more about APO-Easy® and our other diagnostic solutions.